Highlights Jun 8 - Jun 14, 2026
new every Sunday
This week brought early clinical and preclinical signals for psilocybin in suicidal ideation and Alzheimer's, alongside evidence refining psychosis and flashback risks. A poisoning outbreak and a new global study underscored the need for better product safety and real-world data.
-
01
A single dose of psilocybin shows months-long reductions in chronic suicidal ideation, with a small new study reporting durable effects and manageable acute risks
A small study found one supported psilocybin dose reduced chronic suicidal ideation for months, with manageable acute risks.
-
02
Psilocybin restores cognitive function and synaptic density in an Alzheimer's mouse model, with stronger gains after low-dose treatment before plaque onset
In an Alzheimer's mouse model, early low-dose psilocybin produced the strongest gains in memory, connectivity, and synaptic density.
-
03
Baseline psychiatric history confounds observed links between hallucinogen use and later psychosis in population data, reducing evidence for a direct causal association
Population analyses found that prior psychiatric vulnerability explains part of the observed link between hallucinogens and later psychosis.
-
04
An Amanita mushroom poisoning outbreak in New York City traces severe illness to mislabeled toxic mushrooms sold as psilocybin edibles
A New York City outbreak traced severe illness to toxic Amanita mushrooms sold as psilocybin edibles, exposing labeling and testing gaps.
-
05
Psychedelic flashbacks correlate with elevated risk of functional somatic syndromes, with stronger links among women and people with severe visual effects
Survey data linked psychedelic flashbacks with functional somatic syndromes, especially in women and people with severe visual effects.
-
06
Largest real-world psychedelic study launches to track mental health, wellbeing, and outcomes across naturalistic use at unprecedented global scale
A large global study will track mental health, context, benefits, and harms around psychedelic use outside controlled clinical trials.
-
07
Utah HB 390 advances state-backed psychedelic research for veterans with PTSD through a task force, clinical planning, and a two-year implementation path
Utah's HB 390 creates a task force and two-year path to study psychedelic-assisted PTSD treatment for veterans.